Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 9, 2024
Distillery Therapeutics

Inhibiting ARRB2 for MASH and MASLD

BioCentury | Feb 21, 2024
Distillery Therapeutics

Increasing Kupffer cell GPR3 activation for obesity

BioCentury | Feb 7, 2020
Translation in Brief

Gilead’s remdesivir vs. 2019-nCov in cells; plus Syndax, Syntrix and Max Planck

BioCentury's roundup of preclinical news
BioCentury | Jan 17, 2018
Distillery Techniques

Drug platforms

BioCentury | Jan 3, 2017
Distillery Therapeutics

Neurology; dermatology

BioCentury | Nov 15, 2016
Distillery Techniques

Chemistry

BioCentury | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

Why the MS field might invest in biased opioid agonists
BioCentury | Sep 1, 2016
Targets & Mechanisms

Biased against pain

How Epiodyne aims to make opioids safer
Items per page:
1 - 10 of 20